VTGN
$0.87
Vistagen Therap. Com
($.03)
(2.80%)
VTGN
Earnings Whisper ®
N/A
1st Quarter June 2022
Consensus:  ($0.09)
Revenue:  N/A
Thursday
Sep 22
4:20 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VTGN reports earnings?
Beat
Meet
Miss

Where is VTGN's stock price going from here?
Up
Flat
Down
Stock chart of VTGN
Analysts
Summary of analysts' recommendations for VTGN
Score
Grade
Pivots
Resistance
$1.03
$0.99
$0.94

$0.91

Support
$0.86
$0.83
$0.78
Tweet
Growth
Description
VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.